多糖铁复合物胶囊对比蔗糖铁在血液透析患者中的疗效与安全性:IHOPE随机对照试验方案
本研究为在中国9个血液透析中心开展的随机、开放标签、阳性对照、多中心试验,计划入组186例维持性血液透析患者,比较多糖铁复合物胶囊联合促红素与蔗糖铁注射联合促红素的疗效与安全性,主要终点为第12周转铁蛋白饱和度,治疗持续24周。
要点
- 维持性血液透析合并肾性贫血患者,口服多糖铁复合物对比静脉蔗糖铁。
- 主要终点为第12周转铁蛋白饱和度,治疗随访至24周。
- 入选要求Hb 110–130 g/L、TSAT 20%–50%、SF 200–500 μg/L。
核心结论
- 旨在为口服多糖铁复合物治疗维持性血液透析患者肾性贫血提供疗效与安全性证据。
研究设计与样本
- 随机、开放标签、平行组、阳性对照、多中心试验,中国9个血液透析中心计划入组186例。
- 受试者为18–75岁维持性血液透析患者,随机分入促红素联合多糖铁复合物胶囊组或促红素联合蔗糖铁注射组。
- 治疗持续24周,基线及第4、8、12、16、20、24周随访。
关键数值与推荐
- 试验组:促红素联合多糖铁复合物胶囊每次2粒、每日2次;对照组:促红素联合蔗糖铁100mg、每2周注射。
- 入选标准:Hb≥110g/L且<130g/L,TSAT>20%且<50%,SF>200μg/L且<500μg/L。
- 排除标准包括活动性出血、血清白蛋白<35g/L、HsCRP>10mg/L、iPTH≥800pg/mL。
临床怎么用
- 为维持性血液透析肾性贫血患者口服铁剂与静脉铁剂的选择提供随机对照证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anemia is one of the main complications of chronic kidney disease especially kidney failure, which includes treatment with erythropoiesis-stimulating agents and iron supplementation, including intravenous and oral iron. However, intravenous iron may pose limitations, such as potential infusion reactions. Oral iron is mainly composed of divalent iron, which can excessively stimulate the gastrointestinal tract. Iron polysaccharide complex capsules are a novel oral iron trivalent supplement with higher iron content and lower gastrointestinal irritation. However, since high-quality evidence-based medicinal support is lacking, it is necessary to conduct clinical studies to further evaluate the effectiveness and safety of oral iron polysaccharide complex in chronic kidney disease patients. METHODS: This randomized controlled trial uses an open-label, parallel group design, where the efficacy and safety of maintenance hemodialysis (MHD) participants is evaluated. The experimental group is assigned erythropoietins and iron polysaccharide complex (two capsules each time, bid), and the control group is assigned erythropoietin and sucrose iron (100mg, 2w) injection. Participants (aged 18-75 years) undergoing maintenance hemodialysis were considered for screening. Inclusion criteria included hemoglobin (Hb) ≥110g/L and < 130g/L, transferrin saturation (TSAT) > 20% and < 50%, and serum ferritin (SF) > 200μg/L and < 500μg/L. Exclusion criteria included acute or chronic bleeding, serum albumin < 35g/L, hypersensitive C-reactive protein (HsCRP) > 10 mg/L, and severe secondary hyperparathyroidism (iPTH ≥ 800 pg/mL). Full inclusion and exclusion criteria are described in the "Methods" section. The primary endpoint is TSAT of the participants at week 12. Secondary endpoints include Hb, SF, hematocrit (Hct), HsCRP, pharmacoeconomic evaluation, drug costs, quality of life, and indicators of oxidative stress. The treatment will last for 24 weeks with a follow-up visit at baseline (within 7 days prior to initial treatment) and weeks 4, 8, 12, 16, 20, and 24 after initial treatment. This clinical research includes 9 hemodialysis centers in mainland China and plans to enroll 186 participants. DISCUSSION: It is expected that it will provide strong evidence to reveal the clinical efficacy and safety of oral iron in the treatment of chronic CKD-related anemia in MHD patients through this clinical trial. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000031166 . Registered on March 23, 2020.
引用
- Lu R, Zhang X, Cai X, et al. Efficacy and safety of polysaccharide iron complex capsules compared with iron sucrose in hemodialysis patients: study protocol for a randomized, open-label, positive control, multicenter trial (IHOPE). Trials. 2021. PMID: 34629085. doi:10.1186/s13063-021-05663-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。